Sensorion   Report issue

For profit Phase 1 Phase 3
Founded: Clapier France (2009)

Organization Overview

First Clinical Trial
2016
NCT02772796
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Sensorion | Sensorion SA

Active Ingredients

Drugs in Phase 3 Trials (2)

dolasetron (anzemet) (4 trials)

Seliforant (1 trial)

Drugs in Phase 1 Trials (1)

azasetron (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 3)

Ear Diseases (Phase 1)

Hearing Loss (Phase 3)

Hearing Loss, Sensorineural (Phase 3)

Labyrinth Diseases (Phase 1)

Labyrinthitis (Phase 1)

Stress, Psychological (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3